Scarica l'app Stockscreener
19.88
13.41%
2.35
Dopo l'orario di chiusura:
20.00
0.12
+0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$17.53
Aprire:
$17.66
Volume 24 ore:
3.99M
Relative Volume:
1.81
Capitalizzazione di mercato:
$1.82B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-10.98
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+18.62%
1M Prestazione:
+22.79%
6M Prestazione:
-19.51%
1 anno Prestazione:
-11.92%
Intervallo 1D:
$17.66
$20.14
Intervallo di 1 settimana:
$16.49
$20.14
Portata 52W:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
19.88 | 1.82B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus
Beam reports positive results from sickle cell disease treatment - Seeking Alpha
Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener
Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria
Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus
New Clinical Data: BEAM's Sickle Cell Gene Therapy Achieves Remarkable 60%+ Success Metric in All Patients - Stock Titan
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab - Benzinga
ARK Investment Acquires 349K Shares of Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
Tesla’s Driverless Robotaxis Are Operating On Texas Streets - The Globe and Mail
Beam Therapeutics Confirms Key Decisions at Annual Meeting - TipRanks
Beam Therapeutics Announces Pricing of Underwritten Offering - Revista ADVFN
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - mx.advfn.com
Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com
Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus
Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus
Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Yahoo Finance
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India
FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus
Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan
Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beam Therapeutics Inc Azioni (BEAM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):